Clinical Trial: Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional

Official Title: Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks

Brief Summary: The purpose of this study is to improve port wine stain therapeutic outcome in response to laser therapy. The researcher want to determine whether the combined use of pulsed dye laser therapy and topical ranibizumab will improve port wine stain therapeutic outcome.

Detailed Summary:

Combined use of pulsed dye laser to induce port wine stain blood vessel injury, and ranibizumab to prevent port wine stain blood vessel angiogenesis and recanalization after laser therapy, will improve port wine stain lesion blanching.

After pulsed dye laser treatment of the entire port wine stain, topical ranibizumab will be applied to two of the test sites for two weeks following pulsed dye laser therapy. The degree of port wine stain blanching which will be quantified objectively using visible reflectance spectroscopy measurements. port wine stain test site blanching responses following the combined use of pulsed dye laser and topical ranibizumab will be compared with pulsed dye laser only and with the baseline controls.


Sponsor: University of California, Irvine

Current Primary Outcome: Port Wine Stain response to laser treatment [ Time Frame: 8 weeks ]

Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks


Original Primary Outcome: determine whether the combined use of PDL and topical ranibizumab will improve PWS therapeutic outcome [ Time Frame: 8 weeks ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of California, Irvine

Dates:
Date Received: April 24, 2008
Date Started: March 2008
Date Completion:
Last Updated: February 8, 2017
Last Verified: February 2017